Cytomegalovirus polymerase chain reaction viraemia in patients receiving ganciclovir maintenance therapy for retinitis

AIDS

Volumn 12, Issue 6, 1998, Pages 605-611

  Bowen, E Frances ^a   Emery, Vincent C ^a   Wilson, Pauline ^a   Johnson, Margaret A ^a   Davey, Clare C ^a   Sabin, Caroline A ^a   Farmer, Deborah ^a   Griffiths, Paul D ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Cytomegalovirus; Ganciclovir; Polymerase chain reaction

Indexed keywords

GANCICLOVIR; GLYCOPROTEIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DRUG PENETRATION; DRUG RESISTANCE; GENE SEQUENCE; GENETIC MARKER; HUMAN; MAINTENANCE THERAPY; OPHTHALMOSCOPY; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETINITIS; TREATMENT FAILURE; VIREMIA; VIRUS LOAD;

EID: 0032537103     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199806000-00009     Document Type: Article

References (24)

1. Jacobson MA, O'Donnell JJ, Brodie HR, Wofsy C, Mills J: Randomized prospective trial of ganciclovir maintenance therapy for cytomegalovirus retinitis. J Med Virol 1998, 25:339-349.
2. Kuppermann BD, Quiceno JI, Flores-Aguilar M, et al.: Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: implications for therapy. J Infect Dis 1993, 68:1506-1509.
3. Arevalo JF, Gonzalez C, Capparelli EV, et al.: Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. J Infect Dis 1995, 172:951-956.
4. Drew WL, Ives D, Lalezari JP, et al.: Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group. N Engl J Med 1995, 333:615-620.
5. The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group: Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. Arch Ophthalmol 1996, 114:23-33.
6. Grundy JE, Lui SF, Super M, et al.: Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus. Lancet 1988, 2:132-135.
7. Chou SW: Cytomegalovirus infection and reinfection transmitted by heart transplantation. J Infect Dis 1987, 155:1054-1056.
8. Drew WL, Miner RC, Busch DF, et al.: Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991, 163:716-719.
9. Jacobson MA, Drew WL, Feinberg J, et al.: Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. J Infect Dis 1991, 163:1348-1351.
10. Sullivan V, Talarico CL, Stanat SC, Davis M, Coen DM, Biron KK: A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 1992, 358:162-164.
11. Littler E, Stuart AD, Chee MS: Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 1992, 358:160-162.
12. Chou S, Erice A, Jordan MC, et al.: Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J Infect Dis 1995, 171:576-583.
13. Biron KK: Cytomegalovirus: genetics of drug resistance. Adv Exp Med Biol 1996, 394:135-143.
14. Bowen EF, Wilson P, Cope A, et al.: Cytomegalovirus retinitis in AIDS patients: influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival. AIDS 1996, 10:1515-1520.
15. Bowen EF, Wilson P, Atkins M, et al.: Natural history of untreated cytomegalovirus retinitis. Lancet 1995, 346:1671-1673.
16. Darlington J, Super M, Patel K, Grundy JE, Griffiths PD, Emery VC: Use of the polymerase chain reaction to analyse sequence variation within a major neutralizing epitope of glycoprotein B (gp5 8) in clinical isolates of human cytomegalovirus. J Gen Virol 1991, 72:1985-1989.
17. Fox JC, Griffiths PD, Emery VC: Quantification of human cytomegalovirus DNA using the polymerase chain reaction. J Gen Virol 1992, 73:2405-2408.
18. Wolf DG, Smith IL, Lee DJ, Freeman WR, Flores-Aguilar M, Spector SA: Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma. J Clin Invent 1995, 95:257-263.
19. Bowen EF, Johnson MA, Griffiths PD, Emery VC: Development of a point mutation assay for the detection of human cytomegalovirus UL97 mutations associated with ganciclovir resistance. J Virol Methods 1997, 68:225-234.
20. Kaye S, Loveday C, Tedder RS: A microtitre format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus type-1 infected patients treated with zidovudine. J Med Virol 1992, 37:241-246.
21. SAS Institute: SAS/STAT Users' Guide. Cary: SAS Institute, Inc.; 1989.
22. Meyers JD, Ljungman P, Fisher LD: Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia. J Infect Dis 1990, 162:373-380.
23. Kidd IM, Fox JC, Pillay D, Charman H, Griffiths PD, Emery VC: Provision of prognostic information in immunocompromised patients by routine application of the polymerase chain reaction for cytomegalovirus. Transplantation 1993, 56:867-871.
24. Martin DF, Parks DJ, Mellow SD, et al.: Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial. Arch Ophthalmol 1994, 112:1531-1539.